Of the selected biomarkers, only five of them are significant (p < 0.05): (1) L1CAM primary versus metastatic tumors; (2) KLK6 stage I & II versus III CRC; (3) KLK6 stage III versus IV CRC; (4) ALDH1A1 chemo versus no chemo CRC; and (5) stage IV ALDH1A1 chemo versus no chemo CRC. The gene discussed is KLK6; the disease is metastatic neoplasm.